We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Diagnostics Aid Hologic (HOLX) Q3 Earnings Amid Coronavirus?
Read MoreHide Full Article
Hologic, Inc. (HOLX - Free Report) is slated to report third-quarter fiscal 2020 results on Jul 29, after the closing bell.
In the last-reported quarter, the company’s earnings of 57 cents outpaced the Zacks Consensus Estimate. Moreover, its earnings surpassed the consensus estimate in two of the last four quarters and met the mark in the other two. The trailing four-quarter average surprise was 2.21%.
Let's see how things are shaping up prior to the announcement.
Factors at Play
Lower sales at Breast Health are expected to continue given the changing customer responses amid the COVID-19 outbreak. Additionally, sales of GYN Surgical and certain non COVID-19 Diagnostics products are expected to have been significantly dented in the third quarter due to the deferral of elective procedures and physician office visits.
Overall, the company expects its Diagnostics segment to have maintained a stellar performance in the fiscal third quarter on robust performance by its new Molecular Diagnostics testing products for coronavirus. Notably, in the fiscal third quarter, Hologic received the FDA’s Emergency Use Authorization for its Aptima SARS-CoV-2 assay, which runs on its Panther system. Similar to the fiscal second quarter, the company expects global Molecular Diagnostics revenues in the third quarter to reflect the benefits of additional tests, including the COVID-19 assays, onto Hologic’s Panther installed base.
The Molecular Diagnostics segment is likely to have maintained robust growth in the fiscal third quarter, which in the second quarter was driven by cervical cancer co-testing in Germany and viral load testing in Africa.
The company’s Panther Fusion platform has likely maintained momentum, thus contributing to the top line. The Molecular Diagnostics segment is expected to have witnessed global growth in the quarter on strength in the Panther system.
The Zacks Consensus Estimate for Molecular Diagnostics’ revenues is pegged at $241 million, suggesting a 40.9% increase from the year-ago quarter’s reported level.
Meanwhile, let us delve deeper into how the other core business segments have fared during the third quarter.
GYN Surgical
Hologic is expected to have maintained its U.S. Surgical’s performance in the fiscal third quarter despite continued impact of the pandemic. Notably, the segment recorded a significant impact on demand since late-March as elective procedures were postponed.
Outside the United States, organic revenues are likely to have been strong in the fiscal third quarter as was the case in the second quarter, reflecting strong foundations built by Hologic for sustainable growth. However, some impact on global revenues is likely, given the continuation of the pandemic and widespread lockdowns.
The company confirmed during its fiscal second quarter earnings call that it expects the Surgical segment to be the worst-hit in the short-term. Further, Hologic expects global Surgical sales to decline significantly year over year in April.
The Zacks Consensus Estimate for GYN Surgical’s revenues is pegged at $29.8 million, suggesting a 73.4% drop from the year-ago quarter’s reported level.
Breast Health
Hologic confirmed during its fiscal second-quarter earnings call that it expects April sales at the Breast and Skeletal Health segment to significantly decline from the year-ago period, reflecting the impact of the pandemic. However, the company was hopeful that recurring revenues, such as service, will partially offset the steeper decline in capital sales. Hologic was also optimistic about the gradually relaxing access restrictions worldwide. However, as the pandemic continues unabated, the restrictions are being imposed again. This is likely to reflect on the company’s fiscal third-quarter results.
The Zacks Consensus Estimate for the segment’s revenues is pegged at $219 million, indicating a decline of 32.6% from the prior-year quarter’s figure.
Q3 Estimates
The Zacks Consensus Estimate for third-quarter fiscal 2020 revenues is pegged at $595.9 million, suggesting a 30.1% fall from the year-ago figure.
The Zacks Consensus Estimate for the company’s earnings of 36 cents suggests a 42.9% fall from the year-ago figure.
What Our Model Suggests
Our proven model predicts an earnings beat for Hologic this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Zacks Rank: The company currently carries a Zacks Rank #3.
Earnings ESP: Hologic has an Earnings ESP of +12.27%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Exact Sciences Corporation (EXAS - Free Report) has an Earnings ESP of +6.69% and a Zacks Rank of 2 at present.
Thermo Fisher Scientific Inc. (TMO - Free Report) has an Earnings ESP of +14.37% and is a Zacks #1 Ranked stock.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Can Diagnostics Aid Hologic (HOLX) Q3 Earnings Amid Coronavirus?
Hologic, Inc. (HOLX - Free Report) is slated to report third-quarter fiscal 2020 results on Jul 29, after the closing bell.
In the last-reported quarter, the company’s earnings of 57 cents outpaced the Zacks Consensus Estimate. Moreover, its earnings surpassed the consensus estimate in two of the last four quarters and met the mark in the other two. The trailing four-quarter average surprise was 2.21%.
Let's see how things are shaping up prior to the announcement.
Factors at Play
Lower sales at Breast Health are expected to continue given the changing customer responses amid the COVID-19 outbreak. Additionally, sales of GYN Surgical and certain non COVID-19 Diagnostics products are expected to have been significantly dented in the third quarter due to the deferral of elective procedures and physician office visits.
Hologic, Inc. Price and EPS Surprise
Hologic, Inc. price-eps-surprise | Hologic, Inc. Quote
Overall, the company expects its Diagnostics segment to have maintained a stellar performance in the fiscal third quarter on robust performance by its new Molecular Diagnostics testing products for coronavirus. Notably, in the fiscal third quarter, Hologic received the FDA’s Emergency Use Authorization for its Aptima SARS-CoV-2 assay, which runs on its Panther system. Similar to the fiscal second quarter, the company expects global Molecular Diagnostics revenues in the third quarter to reflect the benefits of additional tests, including the COVID-19 assays, onto Hologic’s Panther installed base.
The Molecular Diagnostics segment is likely to have maintained robust growth in the fiscal third quarter, which in the second quarter was driven by cervical cancer co-testing in Germany and viral load testing in Africa.
The company’s Panther Fusion platform has likely maintained momentum, thus contributing to the top line. The Molecular Diagnostics segment is expected to have witnessed global growth in the quarter on strength in the Panther system.
The Zacks Consensus Estimate for Molecular Diagnostics’ revenues is pegged at $241 million, suggesting a 40.9% increase from the year-ago quarter’s reported level.
Meanwhile, let us delve deeper into how the other core business segments have fared during the third quarter.
GYN Surgical
Hologic is expected to have maintained its U.S. Surgical’s performance in the fiscal third quarter despite continued impact of the pandemic. Notably, the segment recorded a significant impact on demand since late-March as elective procedures were postponed.
Outside the United States, organic revenues are likely to have been strong in the fiscal third quarter as was the case in the second quarter, reflecting strong foundations built by Hologic for sustainable growth. However, some impact on global revenues is likely, given the continuation of the pandemic and widespread lockdowns.
The company confirmed during its fiscal second quarter earnings call that it expects the Surgical segment to be the worst-hit in the short-term. Further, Hologic expects global Surgical sales to decline significantly year over year in April.
The Zacks Consensus Estimate for GYN Surgical’s revenues is pegged at $29.8 million, suggesting a 73.4% drop from the year-ago quarter’s reported level.
Breast Health
Hologic confirmed during its fiscal second-quarter earnings call that it expects April sales at the Breast and Skeletal Health segment to significantly decline from the year-ago period, reflecting the impact of the pandemic. However, the company was hopeful that recurring revenues, such as service, will partially offset the steeper decline in capital sales. Hologic was also optimistic about the gradually relaxing access restrictions worldwide. However, as the pandemic continues unabated, the restrictions are being imposed again. This is likely to reflect on the company’s fiscal third-quarter results.
The Zacks Consensus Estimate for the segment’s revenues is pegged at $219 million, indicating a decline of 32.6% from the prior-year quarter’s figure.
Q3 Estimates
The Zacks Consensus Estimate for third-quarter fiscal 2020 revenues is pegged at $595.9 million, suggesting a 30.1% fall from the year-ago figure.
The Zacks Consensus Estimate for the company’s earnings of 36 cents suggests a 42.9% fall from the year-ago figure.
What Our Model Suggests
Our proven model predicts an earnings beat for Hologic this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Zacks Rank: The company currently carries a Zacks Rank #3.
Earnings ESP: Hologic has an Earnings ESP of +12.27%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Integra LifeSciences Holdings Corporation (IART - Free Report) has an Earnings ESP of +20.69% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Exact Sciences Corporation (EXAS - Free Report) has an Earnings ESP of +6.69% and a Zacks Rank of 2 at present.
Thermo Fisher Scientific Inc. (TMO - Free Report) has an Earnings ESP of +14.37% and is a Zacks #1 Ranked stock.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>